科学界神雕侠侣，“吵”出一款世界级新药

Core Viewpoint - The article highlights the collaborative journey of two prominent scientists, Li Wenhui and Sui Jianhua, who have made significant contributions to the field of virology and antibody engineering, culminating in the development of the first monoclonal antibody drug for viral hepatitis, Libeweita [3][4][12]. Group 1: Scientific Contributions - Li Wenhui was the first to discover the receptor for the SARS virus and the hepatitis B virus, while Sui Jianhua was the first to design human antibodies against these viruses [3][4]. - During the COVID-19 pandemic, they collaborated on a broad-spectrum anti-COVID drug, although it was not developed further due to the pandemic's resolution [3][4]. - The monoclonal antibody drug Libeweita is set to be approved in January 2026, marking a significant milestone in the treatment of viral hepatitis [3][4]. Group 2: Personal and Professional Journey - Li and Sui met at Lanzhou University over 30 years ago and have since maintained a close professional relationship, often engaging in scientific debates that drive their research forward [11][15]. - They both pursued postdoctoral research at Harvard University, where their paths converged in the study of viral infections and antibody development [6][10]. - Their partnership is characterized by a seamless integration of their respective expertise, with Li focusing on the mechanisms of viral infections and Sui on antibody engineering [12][17]. Group 3: Company Formation and Vision - In 2015, they co-founded Huahui Anjian, a company aimed at developing innovative drugs for liver diseases, reflecting their shared scientific aspirations [16]. - Li primarily handles basic scientific discoveries while Sui manages the company's operations and clinical trials, showcasing their complementary roles [16][17]. - Their discussions often revolve around company matters, with a dynamic of questioning and critical thinking that fosters innovation [16][17].